Navigation Links
Peptimmune Announces the Second Close of Series D Private Financing
Date:7/16/2008

CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

"The Series D investment allows us to further evaluate PI-2301 in multiple sclerosis patients," stated Thomas P. Mathers, President and CEO. "The primary goal of our current Phase Ib study is to demonstrate safety of PI-2301 in multiple sclerosis patients. The Phase Ib will investigate the pharmacologic effect of PI-2301 in MS patients in the most extensive study of biomarkers in patients treated with copolymers to date."

Financing Clinical Trials in Multiple Sclerosis

Peptimmune is currently undertaking its Phase Ib multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in 2009.

About PI-2301

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 h
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Newswire/ -- By now, most people have heard of the...to grow in popularity. And, the latest product on ...te - the new single piece PremiumOne(TM) disposabl...e of $14.99. ,, "This new product makes it poss...ow price, before making a bigger investment in a s...
(Date:12/2/2009)...resent Diverse Healthcare Stakeholders ,, WA...mbership of the National Quality Forum (NQF) elect...reappointed four current Board members. The new Bo...takeholders, including consumers, providers, purch...thcare. ,, The newly elected Board members fil...
(Date:12/2/2009)...e/ -- Independence Blue Cross (IBC) today announce...nancial Group. IBC will be the primary provider of... Financial Group employees, retirees, and their de...ings will include the PPO option and Comprehensive...l of us at Independence Blue Cross when I say we a...
(Date:12/2/2009)...ifornia Institute of Technology (Caltech) have bee...the previously mysterious process by which long ch...zymes called ubiquitin ligases to proteins that co...proteins for destruction by protein-degrading comp...gases build ubiquitin chains very rapidly by trans...
(Date:12/2/2009)...the European Association of Echocardiography (EAE)...ardiology, where techniques of non-invasive diagno...rts will be presented at this year,s Congress, wit...s new technology. , Now, with such rapid develo...-invasive imaging will gain more importance in cli...
Breaking Medicine News(10 mins):Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 2Health News:Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:Media alert: EUROECHO 2009 2
...CETON, N.J., July 23 The New Jersey,Hospital Asso... has,received a planning grant for $199,502 from t...p a proposal for improving the quality of,healthca... initiative,which is focused on lifting the overal...
...ANG, China, July 23 /Xinhua-PRNewswire-FirstCall/ ...Bulletin Board: GTEC) ("Genesis" or,the "Company")... Republic,of China, held a Board of Directors meet...ation Committee were formed., Mr. Michael Marks w...
...PETERSBURG, Fla., July 23 Laura Kolkman, Presiden... information exchange,consulting firm, has been se...tion and Management Systems Society (HIMSS) Health... payers, vendors, consultants and life,sciences, l...
...AGO, July 23 A new survey of employers by the,non...nds the new Illinois,smoking cessation law, the Sm...employees overcome some barriers, but removing smo...ployer involvement in reducing tobacco,use among w...
...icking up on innuendo and social cues is a central... with autism often struggle to determine another p...search from Carnegie Mellon University sheds light...us. , According to the study, which is available...
... Online Clinicians Guide to ...Edison Pharma , Boston (P...day the completion of the Clinicians Symptom Guide... by mitochondrial disease. The Clinicians Symptom ...
Other Medicine News:Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 3Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers 2
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...rch report is available in its catalogue: ,, E...rspective ,, http://www.reportlinker.com/p016...ket-Perspective.html ,, Electrodes in electron...muscle and nerve cells that are created by chemica...
(Date:12/2/2009)..., , FRAZER, Pa., Dec. 2 /PRNewswire-Fi...announced that it has filed a lawsuit in U.S. Dist...s USA, Inc. for infringement of U.S. Patent Nos. 7... Patent") and RE37,516 (the ",516 Patent") for the...ets [C-IV]. Cephalon has a three-year period of m...
(Date:12/2/2009)..., , NEW YORK, Dec. 2 ...rch report is available in its catalogue: ,, H..., http://www.reportlinker.com/p0164230/Hemoglo..., The seriousness of affliction and the need for...he emergence of a significant market for monitorin...
Breaking Medicine Technology:Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 2Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 3Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 4Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 5Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 6Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 7Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 2Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 3Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 5Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 6Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 7NeoStem Featured on CBS2 News 3B Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems 3B Procedure to be Used by NeoSt 13044 1NeoStem Featured on CBS2 News 3B Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems 3B Procedure to be Used by NeoSt 13044 2NeoStem Featured on CBS2 News 3B Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems 3B Procedure to be Used by NeoSt 13044 3NeoStem Featured on CBS2 News 3B Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems 3B Procedure to be Used by NeoSt 13044 4Versus Technology Inc Partners With Microsoft 28R 29 To Promote Health Care Automation in Windows 7 Computing Environments 51774 1Versus Technology Inc Partners With Microsoft 28R 29 To Promote Health Care Automation in Windows 7 Computing Environments 51774 2Versus Technology Inc Partners With Microsoft 28R 29 To Promote Health Care Automation in Windows 7 Computing Environments 51774 3Schering Plough Expands Vicriviroc Phase II Study in Treatment Naive Patients With HIV 4727 1Schering Plough Expands Vicriviroc Phase II Study in Treatment Naive Patients With HIV 4727 2Schering Plough Expands Vicriviroc Phase II Study in Treatment Naive Patients With HIV 4727 3Schering Plough Expands Vicriviroc Phase II Study in Treatment Naive Patients With HIV 4727 4Schering Plough Expands Vicriviroc Phase II Study in Treatment Naive Patients With HIV 4727 5
...ewswire-FirstCall/ --,Phosphagenics Limited (AIM: ...nical studies of its TPM-02 dermal drug delivery,t... topical,treatment for severe acne and an active i...f of concept studies showed a three-fold increase ...skin when formulated,with TPM-02 compared to a con...
...USNewswire/ -- Childhood,cancers are fortunately r...se, accounting for 7 percent of all childhood canc... typically occurs as a,solid tumor in the abdomen,...ng in the network of the body,s sympathetic nervou...a heterogeneous disease;,its name includes subtype...
Other Medicine Technology:Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 3
CLEARBLUE EASY OVULATION TEST
Achieva CV
ResMed AutoSet Spirit
BD Vacutainer® Safety-Lok™ Blood Collection Set with Pre Attached Holder
Medicine Products: